We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Read MoreHide Full Article
Key Takeaways
RXRX is expanding a pipeline through pharma, tech and data partnerships while generating non-dilutive funding.
RXRX's Bayer, Roche, Genentech, Sanofi and Merck KGaA deals offer billions in milestones and royalties.
Recursion has built and curated more than 50 petabytes of multimodal data to scale AI-driven drug discovery.
Recursion Pharmaceuticals (RXRX - Free Report) continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive funding to support R&D. As of the second quarter of 2026, RXRX had received more than $500 million in upfront and milestone payments. Recursion's cash, cash equivalents and restricted cash totaled $556.8 million as of the end of June. Based on its current operating plans, the company expects its cash runway to extend into early 2028 without additional financing.
Through its Bayer collaboration, Recursion is advancing precision oncology programs and is eligible for up to $1.5 billion in potential development and commercial milestones, plus tiered royalties. Its partnerships with Roche and its wholly-owned subsidiary, Genentech, cover neuroscience and gastrointestinal oncology and could support up to 40 programs, with each potentially generating more than $300 million in milestones, plus tiered royalties. In the second quarter of 2026, Genentech advanced the first neuroscience target from the collaboration into early discovery. Partnerships with Sanofi and Merck KGaA further diversify its pipeline across oncology and immunology, offering up to $5.2 billion and $674 million, respectively, in potential milestone payments, in addition to royalties.
Recursion is also strengthening its AI infrastructure and capabilities. Its NVIDIA partnership supported the development of BioHive-2, while the 2024 combination with Exscientia enhanced its computational chemistry and automated drug-design capabilities. By August 2026, Recursion has built and curated more than 50 petabytes of multimodal data, supporting its efforts to scale AI-driven drug discovery.
Technology and data partnerships with Google Cloud, Helix, Tempus and HealthVerity further enhance Recursion's platform. These relationships provide access to AI and cloud infrastructure, genomic and clinical data, and real-world patient data that can support drug discovery and clinical development. Collectively, the partnerships broaden Recursion’s technology and data capabilities while creating additional opportunities to advance its pipeline in the long term.
RXRX Faces Competitive Pressure in the TechBio Industry
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) remain notable competitors that combine computational technologies with drug-discovery efforts. Relay's lead candidate, zovegalisib (RLY-2608), is being evaluated in the phase III ReDiscover-2 study for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. RLAY expects to initiate a phase III study of zovegalisib in first-line endocrine-sensitive breast cancer in early 2027, subject to regulatory feedback. Meanwhile, Relay expects to provide additional clinical data and a regulatory update from the phase I/II ReInspire study of zovegalisib in PIK3CA-driven vascular anomalies by year-end 2026.
Meanwhile, Schrödinger continues to advance its proprietary therapeutics portfolio, including SGR-1505, a MALT1 inhibitor in phase I development for relapsed/refractory B-cell malignancies, and SGR-3515, a Wee1/Myt1 co-inhibitor in phase I for advanced solid tumors. SDGR plans to complete its ongoing early-stage studies while seeking strategic partners to advance SGR-1505 and SGR-3515 beyond phase I rather than independently funding additional studies. Both Relay and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
Year to date, RXRX shares have lost 9.6% against the industry’s 8.5% growth. Recursion Pharmaceuticals has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.16, which is less than 4.02 for the industry. The stock is trading significantly below its five-year mean of 3.20.
RXRX Stock Valuation
Image Source: Zacks Investment Research
Loss estimates for 2026 have narrowed from $1.01 to 94 cents per share over the past 60 days. During the same time frame, RXRX’s 2027 loss per share estimates have narrowed from 98 cents to 94 cents.
View the Zacks #1 Rank List
Image: Bigstock
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Key Takeaways
Recursion Pharmaceuticals (RXRX - Free Report) continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive funding to support R&D. As of the second quarter of 2026, RXRX had received more than $500 million in upfront and milestone payments. Recursion's cash, cash equivalents and restricted cash totaled $556.8 million as of the end of June. Based on its current operating plans, the company expects its cash runway to extend into early 2028 without additional financing.
Through its Bayer collaboration, Recursion is advancing precision oncology programs and is eligible for up to $1.5 billion in potential development and commercial milestones, plus tiered royalties. Its partnerships with Roche and its wholly-owned subsidiary, Genentech, cover neuroscience and gastrointestinal oncology and could support up to 40 programs, with each potentially generating more than $300 million in milestones, plus tiered royalties. In the second quarter of 2026, Genentech advanced the first neuroscience target from the collaboration into early discovery. Partnerships with Sanofi and Merck KGaA further diversify its pipeline across oncology and immunology, offering up to $5.2 billion and $674 million, respectively, in potential milestone payments, in addition to royalties.
Recursion is also strengthening its AI infrastructure and capabilities. Its NVIDIA partnership supported the development of BioHive-2, while the 2024 combination with Exscientia enhanced its computational chemistry and automated drug-design capabilities. By August 2026, Recursion has built and curated more than 50 petabytes of multimodal data, supporting its efforts to scale AI-driven drug discovery.
Technology and data partnerships with Google Cloud, Helix, Tempus and HealthVerity further enhance Recursion's platform. These relationships provide access to AI and cloud infrastructure, genomic and clinical data, and real-world patient data that can support drug discovery and clinical development. Collectively, the partnerships broaden Recursion’s technology and data capabilities while creating additional opportunities to advance its pipeline in the long term.
RXRX Faces Competitive Pressure in the TechBio Industry
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) remain notable competitors that combine computational technologies with drug-discovery efforts. Relay's lead candidate, zovegalisib (RLY-2608), is being evaluated in the phase III ReDiscover-2 study for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. RLAY expects to initiate a phase III study of zovegalisib in first-line endocrine-sensitive breast cancer in early 2027, subject to regulatory feedback. Meanwhile, Relay expects to provide additional clinical data and a regulatory update from the phase I/II ReInspire study of zovegalisib in PIK3CA-driven vascular anomalies by year-end 2026.
Meanwhile, Schrödinger continues to advance its proprietary therapeutics portfolio, including SGR-1505, a MALT1 inhibitor in phase I development for relapsed/refractory B-cell malignancies, and SGR-3515, a Wee1/Myt1 co-inhibitor in phase I for advanced solid tumors. SDGR plans to complete its ongoing early-stage studies while seeking strategic partners to advance SGR-1505 and SGR-3515 beyond phase I rather than independently funding additional studies. Both Relay and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
RXRX’s Stock Price, Valuation & Estimate Movements
Year to date, RXRX shares have lost 9.6% against the industry’s 8.5% growth. Recursion Pharmaceuticals has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.16, which is less than 4.02 for the industry. The stock is trading significantly below its five-year mean of 3.20.
RXRX Stock Valuation
Loss estimates for 2026 have narrowed from $1.01 to 94 cents per share over the past 60 days. During the same time frame, RXRX’s 2027 loss per share estimates have narrowed from 98 cents to 94 cents.
RXRX Estimate Movement
Recursion Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.